Better Patient Outcomes.
Better Safety Profiles.
Innovative Pipeline
We are developing a portfolio of internally discovered next generation innovative therapies using integrated chemical genomics-driven approaches and proprietary chemistries for diseases with unmet needs.
We have multiple products in our pipeline at various stages of development for chronic conditions in large therapeutic areas.
Program
- Brilaroxazine
Serotonin / dopamine modulator (NCE) - RP1208
Triple reuptake inhibitor (NCE)
Indication
- Schizophrenia*
- Bipolar Disorder
- Major Depressive Disorder
- ADHD
- Pulmonary Arterial Hypertension
- Idiopathic Pulmonary Fibrosis
- Depression
- Obesity
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III
- Schizophrenia
- Bipolar Disorder
- Major Depressive Disorder
- ADHD
- Pulmonary Arterial Hypertension
- Idiopathic Pulmonary Fibrosis
- Depression
- Obesity

*Ongoing. In January 2022, we began a pivotal Phase 3 study in acute schizophrenia and a long-term safety study in stable schizophrenia patients.